| Autor: |
Sousa-Pinto, B. Azevedo, L.F. Jutel, M. Agache, I. Canonica, G.W. Czarlewski, W. Papadopoulos, N.G. Bergmann, K.-C. Devillier, P. Laune, D. Klimek, L. Anto, A. Anto, J.M. Eklund, P. Almeida, R. Bedbrook, A. Bosnic-Anticevich, S. Brough, H.A. Brussino, L. Cardona, V. Casale, T. Cecchi, L. Charpin, D. Chivato, T. Costa, E.M. Cruz, A.A. Dramburg, S. Durham, S.R. De Feo, G. Gerth van Wijk, R. Fokkens, W.J. Gemicioglu, B. Haahtela, T. Illario, M. Ivancevich, J.C. Kvedariene, V. Kuna, P. Larenas-Linnemann, D.E. Makris, M. Mathieu-Dupas, E. Melén, E. Morais-Almeida, M. Mösges, R. Mullol, J. Nadeau, K.C. Pham-Thi, N. O’Hehir, R. Regateiro, F.S. Reitsma, S. Samolinski, B. Sheikh, A. Stellato, C. Todo-Bom, A. Tomazic, P.V. Toppila-Salmi, S. Valero, A. Valiulis, A. Ventura, M.T. Wallace, D. Waserman, S. Yorgancioglu, A. De Vries, G. van Eerd, M. Zieglmayer, P. Zuberbier, T. Pfaar, O. Almeida Fonseca, J. Bousquet, J. |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Popis: |
Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs. Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air®, and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials. © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
